Keratoconus Treatment Market Size

Global Keratoconus Treatment Market Overview

Keratoconus Treatment Market Size was valued at USD 0.3 Billion in 2022. The Keratoconus Treatment market is projected to grow from USD 0.31 Billion in 2023 to USD 0.41 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.70% during the forecast period (2023 - 2032). Rising exposure to sun & UV rays and government aid are the prime market drivers helping the market to grow.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Keratoconus Treatment Market Trends

• Growing sun exposure and UV radiations is driving the market growth

The market CAGR for keratoconus treatment is expanding at an very fast rate due to the rise in sun exposure. As per a study published in the Open Opthalmology Journal titled "Epidemiology of Keratoconus Worldwide," UV light is one of the main factors contributing to the development of keratoconus because of the oxidative damage it produces. This is due to the heavy spread of keratoconus in hot, sunny climates. Saudi Arabia, Iran, New Zealand, Israel, and various Pacific Islands have higher rates of keratoconus than other countries. The sun's and UV rays intense exposure is to blame for this. Resultantly, the likelihood that someone would develop a keratoconus condition is increased by exposure to UV radiation and sunlight.

Additionally, the prevalence of keratoconus condition has increased globally. The prevalence and frequency of keratoconus problems are rising, which has a knock-on effect on the need for various treatment alternatives such lenses, operations, and corneal cross-linking. The American Journal of Ophthalmology reports that 50 to 200 out of every 100,000 people have keratoconus. About 54.5 per 100,000 people in the United States have this condition. Additionally, this illness affects about 3 million people worldwide. As a result, increasing keratoconus patients encourage the usage of various therapeutic approaches such intacs and corneal transplants, driving market expansion.

The market for keratoconus therapies is expanding as a result of the FDA's increasing approval of various novel medications and treatments. For instance, in February 2019, Bausch + Lomb got 510(k) clearance for the Tangible Hydra-PEG Custom Contact Lens Coating Technology on the Zenlens Family of Scleral Lenses and Boston Gas Permeable Lens Materials. With the use of this coating technology, a number of eye care professionals can give their patients better contact lens customisation using these Bausch + Lomb lens options. Additionally, Bausch & Lomb reported that in December 2016, its Specialty Vision Products division introduced the Zenlens diagnostic lenses in a new 28-lens set configuration. The new 28 lens set includes four diagnostic lenses with toric peripheral curves as an addition. Thus, driving the Keratoconus Treatment market revenue.

Keratoconus Treatment Market Segment Insights

Keratoconus Treatment, Keratoconus Type Insights

The Keratoconus Treatment Market segmentation, based on keratoconus type includes Corneal Hydrops, Frome Fruste Keratoconus, Posterior Keratoconus, Keratoglobus, and Pellucid Marginal Degeneration. The market's largest contributor, corneal hydrops, is anticipated to expand at a CAGR of 5.20% over the projection period. A kind of advanced keratoconus called corneal hydrops is characterised by the sudden development of severe corneal opacification brought on by edoema. Transplanting a cornea can be used to cure corneal hydrops. Due to the delicate cornea, Descemet's membrane spontaneously breaks, causing edoema and a severely low level of visual acuity.

Keratoconus Treatment, Treatment Type Insights

The Keratoconus Treatment Market segmentation, based on treatment type, includes Lenses, Surgery, and Colonial cross-linking. The market's largest contributor, colonial cross-linking, is anticipated to expand at a CAGR over the forecast period. In order to stop the surface of the eye from bulging, this procedure, also known as corneal collagen cross-linking or CXL, strengthens the corneal tissue in keratoconus patients.  

Keratoconus Treatment End User Insights

The Keratoconus Treatment Market segmentation, based end user, includes hospitals, and eye clinics. The market's largest contributor, eye clinics, are anticipated to expand fastest over the projection period. The most advanced eye treatments nowadays are best performed at eye clinics. The ophthalmologist gives patients the best possible therapeutic advice based on the condition of the patient's condition.

 Figure 1: Keratoconus Treatment Market, by End User, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Keratoconus Treatment Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Keratoconus Treatment market area will dominate this market, owing to market initiatives taken by key manufacturers. In addition, the region is estimated to grow due to formation of new drugs.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: KERATOCONUS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Keratoconus Treatment market accounts for the second-largest market share due to the thriving healthcare industry and the increase in cases of keratoconus. Further, the German Keratoconus Treatment market held the largest market share, and the UK Keratoconus Treatment market was among the fastest-growing market in the European region

The Asia-Pacific Keratoconus Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. The growth is attributed to the rise in ocular disorder cases. Moreover, China’s Keratoconus Treatment market held the largest market share, and the Indian Keratoconus Treatment market was among the fastest-growing market in the Asia-Pacific region.

Keratoconus Treatment Key Market Players & Competitive Insights

Leading market players are focusing on attempts to broaden and innovate their product offerings, which will lead the Keratoconus Treatment market, even faster. Market players are also undetaking business strategies to gain a leading position, with key market developments tactics including new product developments & upgrades, contractual agreements, mergers & acquisitions, collaborations, higher investments, and collaboration with other organizations. To grow and survive in a competitive and rising market climate, the Keratoconus Treatment industry must provide cost-effective items.

The manufacturers are laying emphasis on the use of local resources to achieve operational efficiency in the global Keratoconus Treatment industry to benefit clients and increase the market sector. In recent years, the Keratoconus Treatment industry has offered some of the most significant benefits to medicine. Major players in the Keratoconus Treatment market, including HOYA vision care company, Menicon Co., Ltd., Cooper companies Inc., Baush Health, SynergEyes, Carl Zeiss Meditec AG, Contamac, Seed Co., Ltd., Novartis AG, Johnson & Johnson Services, Inc., and others, are attempting to increase market demand by investing in research and development operations.

The Cooper Companies Inc. (Cooper) is a manufacturer of medical devices with a concentration on the vision care and women's healthcare industries. For various visual impairments such near- and farsightedness, presbyopia, myopia, astigmatism, ocular dryness, and eye fatigues, the firm develops, manufactures, and markets a variety of soft contact lenses, including spherical, toric, and multifocal lenses. Additionally, it provides genetics, fertility treatments, diagnostics, and contraception to enhance the health of mothers, infants, and families. Through a network of field sales reps, independent agents, and distributors, the firm distributes its eye care products to ophthalmologists, optometrists, opticians, optical chains, and distributors as well as its medical equipment to hospitals and fertility clinics. In November 2022, CooperVision has added SynergEyes to its CooperVision specialist EyeCare business segment, strengthening its commitment to promoting the use of specialist contact lenses in North America and around the world. The hybrid lens methods and brands offered by the Carlsbad, California-based company cover the treatment of uneven cornea, presbyopia, and astigmatism.

Manufacturer, distributor, marketer, importer, and exporter of ophthalmic goods is Menicon Co Ltd (Menicon). The company's product line also includes bifocal contact lenses, soft contact lenses, astigmatic contact lenses, and hard lenses. Additionally, Menicon offers disposable contact lenses, periodic replacement types of lenses, and lens care supplies. The business runs initiatives for intraocular lens research and development. Hospitals, ophthalmology clinics, optical stores, and pharmaceutical wholesalers are among the clients of Menicon. The business imports dry foods and exports food-related materials. It develops materials, designs lenses, and manufactures contact lenses, along with the care products that go with them. In May 2023, Menicon Co., Ltd. announces that Itabashi Medical (Dalian) Co., Ltd., a Chinese affiliate, introduced "ROSE K®" in China in April 2023. A hard contact lens for keratoconus patients is called ROSE K®. Worldwide, more than 90 nations have purchased about 1.67 million ROSE K® lenses. These lenses are sold as "Menicon Rose K-T" and have been approved for "keratoconus use" in Japan. They are produced at the Menicon facility as well as at certified factories across the world with Menicon as a licence holder.

 Key Companies in the Keratoconus Treatment market include

• HOYA vision care company,


• Menicon Co., Ltd.,


• Cooper companies Inc.,


• Baush Health,


• SynergEyes,


• Carl Zeiss Meditec AG,


• Contamac,


• Seed Co., Ltd.,


• Novartis AG,


• Johnson & Johnson Services, Inc.

Keratoconus Treatment Industry Developments

April 2023 Michael W. Belin, MD, CMO of CXL Ophthalmics, Inc., a clinical-stage business creating a minimally invasive keratoconus treatment, will deliver the Plenary Session at the first International Keratoconus Academy (IKA) Symposium. The conference, which will bring together optometrists, ophthalmologists, and business specialists interested in the management and treatment of keratoconus, will take place on April 22 and 23 in Scottsdale, Arizona.

Keratoconus Treatment Market Segmentation

Keratoconus Treatment, Keratoconus Type Outlook

• Corneal Hydrops


• Frome Fruste Keratoconus


• Posterior Keratoconus,


• Keratoglobus


• Pellucid Marginal Degeneration

Keratoconus Treatment, Treatment Type Outlook

• Lenses


• Surgery


• Colonial cross-linking

Keratoconus Treatment End User Outlook

• Hospitals


• Eye Clinics

Keratoconus Treatment Regional Outlook

• 
  North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America